1. Executive Summary
1.1. Market Outlook
1.2. Analysis and Recommendations

2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations

3. Market Background
3.1. Macro-Economic Factors
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity Analysis
3.1.4. Trends

4. Market Context
4.1. Global Healthcare Market Outlook
4.2. Global Canine Arthritis Treatment Scenario
4.3. Pet Ownership in European Union (EU)
4.4. Share of Household Owing at least one Dog in European Union (EU)
4.5. Spending on Health of Pets
4.6. Vet care Spending on Dogs
4.7. Key Regulations and Guidelines

5. Global Canine Arthritis Treatment Market (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029
5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018
5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
5.2.3. Market Value Comparison

6. Global Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029, by Treatment Type
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014-2018
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2019 - 2029
6.3.1. Non-steroidal anti-inflammatory Medications (NSAIDs)
6.3.2. Opioids
6.3.3. Stem Cell Therapy
6.3.3.1. Allogeneic Stem Cells
6.3.3.2. Autologous Stem Cells
6.4. Market Attractiveness Analysis By Treatment Type

7. Global Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029, by Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2014-2018
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2019 - 2029
7.3.1. Oral
7.3.2. Injectable
7.4. Market Attractiveness Analysis By Route of Administration

8. Global Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029, by Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2014-2018
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2019 - 2029
8.3.1. Veterinary Hospital and Clinics
8.3.2. Retail Pharmacies
8.3.3. Drug Stores
8.3.4. E-Commerce
8.3.5. Market Attractiveness Analysis By Distribution Channel

9. Global Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029, by Region
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018
9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. Asia-Pacific Excluding Japan
9.3.5. Japan
9.3.6. Middle East and Africa
9.4. Market Attractiveness Analysis By Region

10. North America Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
10.3.1. By Country
10.3.1.1. U.S.
10.3.1.2. Canada
10.3.2. By Treatment Type
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Market Attractiveness Analysis
10.4.1. By Country
10.4.2. By Treatment Type
10.4.3. By Route of Administration
10.4.4. By Distribution Channel

11. Latin America Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
11.3.1. By Country
11.3.1.1. Mexico
11.3.1.2. Brazil
11.3.1.3. Rest of Latin America
11.3.2. By Treatment Type
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Treatment Type
11.4.3. By Route of Administration
11.4.4. By Distribution Channel

12. Europe Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
12.3.1. By Country
12.3.1.1. Germany
12.3.1.2. Italy
12.3.1.3. France
12.3.1.4. U.K.
12.3.1.5. Spain
12.3.1.6. Russia
12.3.1.7. Rest of Europe
12.3.2. By Treatment Type
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Treatment Type
12.4.3. By Route of Administration
12.4.4. By Distribution Channel

13. APEJ Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
13.3.1. By Country
13.3.1.1. China
13.3.1.2. India
13.3.1.3. Australia & New Zealand
13.3.1.4. ASEAN
13.3.1.5. Rest of APEJ
13.3.2. By Treatment Type
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Treatment Type
13.4.3. By Route of Administration
13.4.4. By Distribution Channel

14. Japan Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
14.3.1. By Treatment Type
14.3.2. By Route of Administration
14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Treatment Type
14.4.2. By Route of Administration
14.4.3. By Distribution Channel

15. Middle East and Africa Canine Arthritis Treatment Market Analysis 2014-2018 and Forecast 2019-2029
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019 - 2029
15.3.1. By Country
15.3.1.1. GCC Countries
15.3.1.2. South Africa
15.3.1.3. Rest of MEA
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Treatment Type
15.4.3. By Route of Administration

16. Competition Analysis
16.1. Competition Dashboard
16.2. Competition Deep Dive
16.2.1. Elanco (Eli Lily and Company)
16.2.1.1. Overview
16.2.1.2. Product Portfolio
16.2.1.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.1.4. Sales Footprint
16.2.1.5. Strategy Overview
16.2.1.5.1. Marketing Strategy
16.2.1.5.2. Product Strategy
16.2.1.5.3. Route of Administration Strategy
16.2.2. Ceva Santé Animale
16.2.2.1. Overview
16.2.2.2. Product Portfolio
16.2.2.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.2.4. Sales Footprint
16.2.2.5. Strategy Overview
16.2.2.5.1. Marketing Strategy
16.2.2.5.2. Product Strategy
16.2.2.5.3. Route of Administration Strategy
16.2.3. Vetoquinol S.A
16.2.3.1. Overview
16.2.3.2. Product Portfolio
16.2.3.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.3.4. Sales Footprint
16.2.3.5. Strategy Overview
16.2.3.5.1. Marketing Strategy
16.2.3.5.2. Product Strategy
16.2.3.5.3. Route of Administration Strategy
16.2.4. Norbrook Laboratories Limited
16.2.4.1. Overview
16.2.4.2. Product Portfolio
16.2.4.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.4.4. Sales Footprint
16.2.4.5. Strategy Overview
16.2.4.5.1. Marketing Strategy
16.2.4.5.2. Product Strategy
16.2.4.5.3. Route of Administration Strategy
16.2.5. Aratana Therapeutics IncMylan Pharmaceuticals Inc.
16.2.5.1. Overview
16.2.5.2. Product Portfolio
16.2.5.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.5.4. Sales Footprint
16.2.5.5. Strategy Overview
16.2.5.5.1. Marketing Strategy
16.2.5.5.2. Product Strategy
16.2.5.5.3. Route of Administration Strategy
16.2.6. Boehringer Ingelheim
16.2.6.1. Overview
16.2.6.2. Product Portfolio
16.2.6.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.6.4. Sales Footprint
16.2.6.5. Strategy Overview
16.2.6.5.1. Marketing Strategy
16.2.6.5.2. Product Strategy
16.2.6.5.3. Route of Administration Strategy
16.2.7. Zoetis Inc
16.2.7.1. Overview
16.2.7.2. Product Portfolio
16.2.7.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.7.4. Sales Footprint
16.2.7.5. Strategy Overview
16.2.7.5.1. Marketing Strategy
16.2.7.5.2. Product Strategy
16.2.7.5.3. Route of Administration Strategy
16.2.8. Bayer AG
16.2.8.1. Overview
16.2.8.2. Product Portfolio
16.2.8.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.8.4. Sales Footprint
16.2.8.5. Strategy Overview
16.2.8.5.1. Marketing Strategy
16.2.8.5.2. Product Strategy
16.2.8.5.3. Route of Administration Strategy
16.2.9. VetStem Biopharma
16.2.9.1. Overview
16.2.9.2. Product Portfolio
16.2.9.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.9.4. Sales Footprint
16.2.9.5. Strategy Overview
16.2.9.5.1. Marketing Strategy
16.2.9.5.2. Product Strategy
16.2.9.5.3. Route of Administration Strategy
16.2.10. Dechra Pharmaceuticals PLC
16.2.10.1. Overview
16.2.10.2. Product Portfolio
16.2.10.3. Profitability by Market Segments (Product/Route of Administration/Region)
16.2.10.4. Sales Footprint
16.2.10.5. Strategy Overview
16.2.10.5.1. Marketing Strategy
16.2.10.5.2. Product Strategy
16.2.10.5.3. Route of Administration Strategy

17. Assumptions and Acronyms Used
18. Research Methodology